Market Cap | 863.35M | P/E | 5.09 | EPS this Y | -63.20% | Ern Qtrly Grth | - |
Income | 179.72M | Forward P/E | 11.56 | EPS next Y | 21.00% | 50D Avg Chg | 2.00% |
Sales | 310.46M | PEG | 0.93 | EPS past 5Y | -6.33% | 200D Avg Chg | 4.00% |
Dividend | N/A | Price/Book | 1.55 | EPS next 5Y | 19.34% | 52W High Chg | -11.00% |
Recommedations | 3.00 | Quick Ratio | 7.28 | Shares Outstanding | 63.23M | 52W Low Chg | 24.00% |
Insider Own | 1.59% | ROA | 7.12% | Shares Float | 51.14M | Beta | 0.58 |
Inst Own | 117.70% | ROE | 28.97% | Shares Shorted/Prior | 11.33M/13.32M | Price | 13.18 |
Gross Margin | 84.09% | Profit Margin | 57.89% | Avg. Volume | 669,608 | Target Price | 15.00 |
Oper. Margin | 53.02% | Earnings Date | May 7 | Volume | 542,807 | Change | -1.35% |
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
EF Hutton | Buy | May 10, 23 |
EF Hutton | Buy | Apr 20, 23 |
Goldman Sachs | Neutral | Mar 3, 23 |
Morgan Stanley | Underweight | Mar 3, 23 |
EF Hutton | Buy | Mar 3, 23 |
Morgan Stanley | Underweight | Jan 24, 23 |
Morgan Stanley | Underweight | Oct 13, 22 |
Morgan Stanley | Underweight | Aug 8, 22 |
Goldman Sachs | Neutral | Jul 20, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
DENNER ALEXANDER J | 10% Owner 10% Owner | Jun 05 | Buy | 13.05 | 15,000 | 195,750 | 7,215,000 | 06/07/23 |
DENNER ALEXANDER J | 10% Owner 10% Owner | May 25 | Buy | 13.07 | 200,000 | 2,614,000 | 7,200,000 | 05/30/23 |
DENNER ALEXANDER J | 10% Owner 10% Owner | May 17 | Buy | 13.2 | 96,000 | 1,267,200 | 7,000,000 | 05/19/23 |
DENNER ALEXANDER J | 10% Owner 10% Owner | May 11 | Buy | 12.3359 | 290,000 | 3,577,411 | 6,904,000 | 05/15/23 |
Raifeld Pavel | Chief Executive Offi.. Chief Executive Officer | Mar 10 | Buy | 10.8677 | 3,000 | 32,603 | 9,799 | 03/14/23 |
Bickerstaff George | Director Director | May 25 | Buy | 13.21 | 20,000 | 264,200 | 124,560 | 05/25/21 |